The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) has contracted with PharmAust Limited to begin designing a regimen in the HEALEY ALS Platform Trial.
A new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine recommends actions Congress, federal agencies, insurers, and others should take to strengthen health care and support services for people with amyotrophic lateral sclerosis (ALS) and accelerate research on therapies for the disease — with the goal of turning ALS into a livable disease within a decade.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Rapa Therapeutics have announced the first participant enrolled in the Expanded Access to RAPA-501 Protocol (EAP). This EAP is sponsored by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS), as part of the U.S. government’s landmark Accelerating Access to Critical Therapies for ALS Act (ACT for ALS).
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Rapa Therapeutics have announced the first participant enrolled in the Expanded Access to RAPA-501 Protocol (EAP). This EAP is sponsored by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS), as part of the U.S. government’s landmark Accelerating Access to Critical Therapies for ALS Act (ACT for ALS).
Clene Nanomedicine, Inc. reported new, significant survival results from two independent analyses of the pooled data from the intermediate-size EAPs supported by Clene.
TPN-101 showed a clinical effect on Vital Capacity, an objective respiratory measure that correlates with mortality in patients with ALS
The NIH has established a transformative national ALS clinical research consortium called Access for All in ALS (ALL ALS). This new consortium is a multi-institutional effort and aims to disrupt the ALS clinical research landscape in the U.S.
